Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales

Zacks10-31

Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479039125?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-10-31 20:42","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479039125","market":"us","top_or_hot":-1,"title":"Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales","media":"Zacks","content":"<div>\n<p>Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/summit-therapeutics-posts-wider-expected-124200955.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/summit-therapeutics-posts-wider-expected-124200955.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/summit-therapeutics-posts-wider-expected-124200955.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"https://finance.yahoo.com/news/summit-therapeutics-posts-wider-expected-124200955.html","article_id":"2479039125","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479039125","pubTimestamp":1730378520,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 cents per share.The reported loss included stock-based compensation expenses. Excluding these expenses, the adjusted loss per share was 5 cents, wider than the year-ago adjusted loss of 3 cents.As the company lacks any marketed product in its portfolio, it did not record quarterly revenues.Adjusted research and development expenses totaled $31.9 million compared with $15.2 million in the year-ago period. This surge was primarily due to anincrease in clinical costs to support the company’s pipeline development.Ivonescimab is being developed in collaboration with China-based Akeso, the drug's original developer. Summit acquired an exclusive license from Akeso in 2022 to develop and market the drug in the United States, Canada, Europe and Japan. The company expanded its licensing deal in June an","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC","LENZ":"Therapeutics","SMMF":"Summit Financial Group"},"translate_title":"Summit Therapeutics第三季度亏损超出预期，销售额为零","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SMMF":1,"SMMT":0.9},"content_text":"Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 cents per share.\nThe reported loss included stock-based compensation expenses. Excluding these expenses, the adjusted loss per share was 5 cents, wider than the year-ago adjusted loss of 3 cents.\nAs the company lacks any marketed product in its portfolio, it did not record quarterly revenues.\nMore on SMMT’s Earnings\nAdjusted research and development expenses totaled $31.9 million compared with $15.2 million in the year-ago period. This surge was primarily due to an increase in clinical costs to support the company’s pipeline development.\nAdjusted general and administrative expenses amounted to $6.8 million, up 42% on a year-over-year basis.\nAs of Sept. 30, 2024, Summit had cash, cash equivalents and short-term investments worth $487 million compared with $326 million as of June 30, 2024. This cash balance rose after management raised $235 million in private financing from multiple leading biotech institutional investors and insiders last month.\nSMMT’s Pipeline Updates\nSummit has only one pipeline drug in its portfolio, ivonescimab, a first-in-class bispecific antibody that targets two proteins, namely PD-1 and VEGF. Summit is currently conducting two late-stage studies, HARMONi and HARMONi-3, evaluating ivonescimab in separate settings for metastatic non-small cell lung cancer (NSCLC) indication.\nAlongside the earnings update, Summit announced that it is amending the design of the HARMONi-3 study, which is evaluating ivonescimab plus chemotherapy in first-line metastatic squamous NSCLC patients against the combination of Merck’s MRK blockbuster oncology drug Keytruda and chemotherapy. The study that previously enrolled NSCLC patients with squamous histologies will now also enroll patients with non-squamous histologies. Earlier there was only one primary endpoint in the study — overall survival (OS). The study has two primary endpoints — OS and progression-free survival (PFS) — now.\nShares of Summit have skyrocketed more than 600% year to date against the industry’s 4.4% decline.\nImage Source: Zacks Investment Research\nEarlier this month, management announced that the HARMONi study has completed enrolment. The study is evaluating ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI). Data from the study is expected in mid-2025.\nIvonescimab is being developed in collaboration with China-based Akeso, the drug's original developer. Summit acquired an exclusive license from Akeso in 2022 to develop and market the drug in the United States, Canada, Europe and Japan. The company expanded its licensing deal in June and now covers Latin America, the Middle East and Africa.\nLast month, Summit reported additional results from the Akeso-sponsored HARMONi-2 study, which evaluated ivonescimab against Merck’s Keytruda in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. Data from the study showed that the treatment with the drug cut the risk of disease progression or death by nearly half compared to Merck’s drug. This data also conforms with the initial results (reported by SMMT in May), wherein treatment with the drug demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival.\nBased on HARMONi-2 results, Summit announced plans to sponsor a late-stage study called HARMONi-7 across several countries, expected to start in early 2025. This study will compare ivonescimab with Merck’s Keytruda in patients with metastatic NSCLC whose tumors have high PD-L1 expression. Based on details posted on a government website, data from this study can be expected in 2027.\n\nSummit Therapeutics PLC Price\n\nSummit Therapeutics PLC price | Summit Therapeutics PLC Quote\n\nSMMT’s Zacks Rank\nSummit currently has a Zacks Rank #4 (Sell).\nKey Picks Among Biotech Stocks\nSome better-ranked stocks from the sector are Castle Biosciences CSTL and Elevation Oncology ELEV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 90 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from $1.28 to 58 cents. Year to date, shares of Castle Biosciences have surged 60.0%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 132.32%.\nIn the past 60 days, estimates for Elevation Oncology’s 2024 loss per share have narrowed from 86 to 82 cents. Loss per share estimates for 2025 have narrowed from 90 to 86 cents during the same time. Year to date, shares of ELEV have rallied 11.7%.\nELEV’s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 12.05%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nSummit Therapeutics PLC (SMMT) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nElevation Oncology, Inc. (ELEV) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479039125"}